On November 3, 2026, a clinical trial involving octreotide was listed with a status update. The study, registered as NCT07913113, is titled "Liver Transplantation Versus Conventional Medical Therapy for Low-Grade GEP-NET With Liver Metastases." It compares liver transplantation against conventional medical therapy in patients with low-grade gastroenteropancreatic neuroendocrine tumors that have spread to the liver. Octreotide is noted as part of the conventional medical therapy arm being evaluated in this comparison. The trial's current status is listed as enrolling by invitation, meaning participation is limited to specific individuals selected by the study team rather than open public enrollment. No phase information was provided for this study. This update reflects only the recruitment status as of the listed date and does not include any outcome or efficacy data. Octreotide remains an approved compound, and this entry does not indicate any change to its approved regulatory status. Readers interested in background on this compound can consult the compound overview for additional context.
Trial Update: Octreotide Arm in Liver Transplant Study for GEP-NET
See the full octreotide overview
Source: https://clinicaltrials.gov/study/NCT07913113